Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 390

1.

Tinagl1 Suppresses Triple-Negative Breast Cancer Progression and Metastasis by Simultaneously Inhibiting Integrin/FAK and EGFR Signaling.

Shen M, Jiang YZ, Wei Y, Ell B, Sheng X, Esposito M, Kang J, Hang X, Zheng H, Rowicki M, Zhang L, Shih WJ, Celià-Terrassa T, Liu Y, Cristea I, Shao ZM, Kang Y.

Cancer Cell. 2019 Jan 14;35(1):64-80.e7. doi: 10.1016/j.ccell.2018.11.016. Epub 2019 Jan 3.

PMID:
30612941
2.

Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV).

Cannon CP, McGuire DK, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Charbonnel B, Shih WJ, Gallo S, Masiukiewicz U, Golm G, Cosentino F, Lauring B, Terra SG; VERTIS-CV Investigators.

Am Heart J. 2018 Dec;206:11-23. doi: 10.1016/j.ahj.2018.08.016. Epub 2018 Sep 5.

3.

Tocopherols inhibit estrogen-induced cancer stemness and OCT4 signaling in breast cancer.

Bak MJ, Furmanski P, Shan NL, Lee HJ, Bao C, Lin Y, Shih WJ, Yang CS, Suh N.

Carcinogenesis. 2018 May 26. doi: 10.1093/carcin/bgy071. [Epub ahead of print]

PMID:
29846560
4.

A phase II trial of riluzole, an antagonist of metabotropic glutamate receptor 1 (GRM1) signaling, in patients with advanced melanoma.

Mehnert JM, Silk AW, Lee JH, Dudek L, Jeong BS, Li J, Schenkel JM, Sadimin E, Kane M, Lin H, Shih WJ, Zloza A, Chen S, Goydos JS.

Pigment Cell Melanoma Res. 2018 Jul;31(4):534-540. doi: 10.1111/pcmr.12694. Epub 2018 Apr 10.

PMID:
29453787
5.

Relative efficiency of precision medicine designs for clinical trials with predictive biomarkers.

Shih WJ, Lin Y.

Stat Med. 2018 Feb 28;37(5):687-709. doi: 10.1002/sim.7562. Epub 2017 Dec 4.

6.

Differential Gene Regulation and Tumor-Inhibitory Activities of Alpha-, Delta-, and Gamma-Tocopherols in Estrogen-Mediated Mammary Carcinogenesis.

Das Gupta S, Patel M, Wahler J, Bak MJ, Wall B, Lee MJ, Lin Y, Shih WJ, Cai L, Yang CS, Suh N.

Cancer Prev Res (Phila). 2017 Dec;10(12):694-703. doi: 10.1158/1940-6207.CAPR-17-0190. Epub 2017 Sep 28.

7.

On study designs and hypotheses for clinical trials with predictive biomarkers.

Shih WJ, Lin Y.

Contemp Clin Trials. 2017 Nov;62:140-145. doi: 10.1016/j.cct.2017.08.014. Epub 2017 Aug 31.

PMID:
28838813
8.

Effects of Soybean Lipid Infusion on Unbound Free Fatty Acids and Unbound Bilirubin in Preterm Infants.

Hegyi T, Kleinfeld A, Huber A, Weinberger B, Memon N, Shih WJ, Carayannopoulos M, Oh W.

J Pediatr. 2017 May;184:45-50.e1. doi: 10.1016/j.jpeds.2016.12.026. Epub 2017 Jan 17.

9.
10.

Methods for flexible sample-size design in clinical trials: Likelihood, weighted, dual test, and promising zone approaches.

Shih WJ, Li G, Wang Y.

Contemp Clin Trials. 2016 Mar;47:40-8. doi: 10.1016/j.cct.2015.12.007. Epub 2015 Dec 7. Review.

PMID:
26674739
11.

Erratum to: Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial.

Bone HG, Dempster DW, Eisman JA, Greenspan SL, McClung MR, Nakamura T, Papapoulos S, Shih WJ, Rybak-Feiglin A, Santora AC, Verbruggen N, Leung AT, Lombardi A.

Osteoporos Int. 2015 Nov;26(11):2721. doi: 10.1007/s00198-015-3274-z. No abstract available.

12.

Dietary γ-Tocopherol-Rich Mixture Inhibits Estrogen-Induced Mammary Tumorigenesis by Modulating Estrogen Metabolism, Antioxidant Response, and PPARγ.

Das Gupta S, Sae-tan S, Wahler J, So JY, Bak MJ, Cheng LC, Lee MJ, Lin Y, Shih WJ, Shull JD, Safe S, Yang CS, Suh N.

Cancer Prev Res (Phila). 2015 Sep;8(9):807-16. doi: 10.1158/1940-6207.CAPR-15-0154. Epub 2015 Jun 30.

13.

Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial.

Bone HG, Dempster DW, Eisman JA, Greenspan SL, McClung MR, Nakamura T, Papapoulos S, Shih WJ, Rybak-Feiglin A, Santora AC, Verbruggen N, Leung AT, Lombardi A.

Osteoporos Int. 2015 Feb;26(2):699-712. doi: 10.1007/s00198-014-2944-6. Epub 2014 Nov 29. Erratum in: Osteoporos Int. 2015 Nov;26(11):2721.

14.

Phase 2 trial of paclitaxel, 13-cis retinoic acid, and interferon alfa-2b in the treatment of advanced stage or recurrent cervical cancer.

Song M, DiPaola RS, Cracchiolo BM, Gibbon DG, Hellmann M, Nieves-Neira W, Vaidya A, Wagreich AR, Shih WJ, Rodriguez-Rodriguez L.

Int J Gynecol Cancer. 2014 Nov;24(9):1636-41. doi: 10.1097/IGC.0000000000000258.

15.

A triple combination of atorvastatin, celecoxib and tipifarnib strongly inhibits pancreatic cancer cells and xenograft pancreatic tumors.

Ding N, Cui XX, Gao Z, Huang H, Wei X, Du Z, Lin Y, Shih WJ, Rabson AB, Conney AH, Hu C, Zheng X.

Int J Oncol. 2014 Jun;44(6):2139-45. doi: 10.3892/ijo.2014.2350. Epub 2014 Mar 19.

16.

Multi-regional clinical trial design and consistency assessment of treatment effects.

Quan H, Mao X, Chen J, Shih WJ, Ouyang SP, Zhang J, Zhao PL, Binkowitz B.

Stat Med. 2014 Jun 15;33(13):2191-205. doi: 10.1002/sim.6108. Epub 2014 Feb 11.

PMID:
24515845
17.

Extension of a Cox proportional hazards cure model when cure information is partially known.

Wu Y, Lin Y, Lu SE, Li CS, Shih WJ.

Biostatistics. 2014 Jul;15(3):540-54. doi: 10.1093/biostatistics/kxu002. Epub 2014 Feb 7.

18.

Methods of designing two-stage winner trials with survival outcomes.

Fang F, Lin Y, Shih WJ, Li Y, Yang J, Zhang X.

Stat Med. 2014 Apr 30;33(9):1539-63. doi: 10.1002/sim.6070. Epub 2013 Dec 18.

19.

Oral caffeine during voluntary exercise markedly inhibits skin carcinogenesis and decreases inflammatory cytokines in UVB-treated mice.

Lou Y, Peng Q, Li T, Nolan B, Bernard JJ, Wagner GC, Lin Y, Shih WJ, Conney AH, Lu Y.

Nutr Cancer. 2013;65(7):1002-13. doi: 10.1080/01635581.2013.812224. Epub 2013 Sep 26.

20.

Feasibility and incremental benefit of puffed-cheek 18F-FDG PET/CT on oral cancer patients.

Chang CY, Yang BH, Lin KH, Liu RS, Wang SJ, Shih WJ.

Clin Nucl Med. 2013 Oct;38(10):e374-8. doi: 10.1097/RLU.0b013e31826390cf.

PMID:
23989442

Supplemental Content

Support Center